The Center for Information and Study on Clinical Research Participation(CISCRP) has announced the upcoming launch of AWARE for All 2021—a free virtual event series designed to educate the general public about clinical trial research and participation. In the series’ second year, CISCRP will host five regional AWARE for All 2021 virtual events across the country from April through November 2021, with a focus on engaging diverse communities to ensure representative and inclusive clinical research for the future.
Each regional AWARE for All 2021 event will focus on select medical conditions and therapeutic areas including but not limited to COVID-19, cancer, heart disease, diabetes, hypertension, and asthma. The events offer participants a 90-minute webinar led by medical professionals, informational videos to help participants better understand the process and importance of clinical research, facilitated conversations with real patients sharing their experiences with clinical trials, and a five-minute exercise break to help encourage healthy habits.
For more information, click here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.